Follistatin

Plain-English version: Follistatin is a protein your body already produces. Think of it as a molecular sponge: it soaks up certain signaling proteins so they can't reach their targets. The most important protein it soaks up is myostatin, which normally tells your muscles "stop growing." Mop up myostatin, and that stop signal fades — which is why researchers have chased follistatin as a way to grow muscle beyond its natural limit.

Follistatin was first identified in 1987 as a "follicle-stimulating hormone (FSH) inhibiting factor" in ovarian fluid — which is where its name comes from (follistatin = FSH-inhibiting protein from follicular fluid). Scientists later found it binds activin, a protein that stimulates FSH, and neutralizes it. The game-changing discovery came when follistatin was also shown to bind and inhibit myostatin (also called GDF-8), the primary negative regulator of skeletal-muscle mass. Overnight, a reproductive-biology protein became one of the most studied molecules in muscle science.

Why myostatin made follistatin famous: In 1997, McPherron and Lee at Johns Hopkins showed that mice bred without a working myostatin gene grew roughly 2–3 times the normal muscle mass — the so-called "mighty mouse" — from both more muscle fibers and bigger ones.^[1] The same natural mutation explains "double-muscled" cattle breeds like the Belgian Blue, and it has even been documented in a human child (more on that below). A few years later, the same lab showed that mice engineered to overexpress follistatin recreated — and actually exceeded — that muscle-bound phenotype.^[2]

The three isoforms you'll see named

The FST gene produces several versions of follistatin through alternative splicing. They share the same core but differ at the tail end, which changes where they act:

• FS-288: sticks to cell surfaces (binds heparan-sulfate proteoglycans) — tissue-bound, local action.
• FS-315: the main version that circulates in blood — lower stickiness, acts more systemically.
• FS-344: the precursor that gets cleaved into FS-315 and FS-288. Because it yields both active forms, it's the isoform used in most research and sold as "follistatin" in the peptide market.

The credibility caveat, stated up front: everything above is real. But there is a wide gap between "follistatin overexpression builds huge muscles in genetically engineered mice" and "injecting follistatin protein builds muscle safely in healthy adults." No follistatin product is FDA-approved, and the injectable protein has never been tested in a formal human trial. For the full legal breakdown, see Are Peptides Legal?

Takeaway first: Follistatin is a "ligand trap." It grabs several growth-limiting proteins in the TGF-β family before they can dock onto muscle-cell receptors. Blocking those signals lets muscle-building cells proliferate and existing fibers enlarge beyond their normal limit. Here is what the verified research shows, mechanism by mechanism.

1. Myostatin (GDF-8) inhibition — the headline mechanism

Myostatin is the body's dedicated brake on muscle size. Follistatin binds it with high (nanomolar) affinity and physically prevents it from activating its receptor complex (ActRIIB with ALK4/5) on muscle cells. With the brake released, satellite cells (muscle stem cells) proliferate and fibers hypertrophy. The foundational proof that this pathway controls muscle mass came from myostatin-knockout mice, which grow 2–3x normal muscle.^[1] Evidence level: genetic mouse models.

2. Activin A and B inhibition — a second brake, and a safety flag

Follistatin also neutralizes activins, and it does so with even higher affinity than it binds myostatin. Activins independently restrain muscle growth, so blocking them adds to the muscle effect. But activins do something else important: they drive FSH secretion from the pituitary, which governs fertility. This is the mechanistic root of follistatin's single biggest safety concern — covered in detail in the Side Effects section. Evidence level: biochemistry and animal models.

3. GDF-11 inhibition — the anti-aging angle (and why it's uncertain)

Follistatin also binds GDF-11, a protein structurally close to myostatin that has been studied in aging. GDF-11's role is genuinely contested — early work framed it as a "rejuvenation factor," while later work suggested it can promote aging in some tissues. Follistatin's inhibition of GDF-11 is why it appears in anti-aging discussions, but this is the least settled part of its biology. Treat it as an open question, not an established benefit.

Why follistatin beats myostatin blockade alone

Here is the key mechanistic insight: follistatin-overexpressing mice grow larger muscles than myostatin-knockout mice.^[2] That's only possible because follistatin blocks more than myostatin — it also traps activin and other TGF-β ligands that each independently limit muscle growth. In other words, follistatin is a broad multi-target inhibitor, not a myostatin-specific one. This breadth is a double-edged sword: broader muscle effect, but also broader off-target risk.^[7]

What we do NOT know

There is no established human pharmacokinetic profile for injectable follistatin protein — how it's absorbed, distributed, and cleared in people — and no human dose-response data. Everything above is real published science, but almost all of it comes from mice, cells, and gene-therapy models, not from people injecting follistatin protein.

How to read this section: for each claimed benefit we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. The honest headline: the muscle-growth evidence is strong in animals and in one small gene-therapy trial, but there is zero controlled human data for the injectable follistatin protein people actually buy.

Muscle growth (best-supported benefit)

Claim: follistatin can substantially increase muscle mass and strength. Mechanism: myostatin, activin, and GDF-11 blockade releasing multiple brakes on muscle growth. Population: genetically engineered mice, then dystrophic (mdx) mice, then nonhuman primates. Effect: follistatin-overexpressing mice grew muscles exceeding even myostatin-knockout animals;^[2] a single AAV-follistatin injection produced sustained muscle-mass and strength gains lasting over two years in wild-type mice and reversed pathology in dystrophic mice, and was well tolerated with no cardiac or reproductive adverse effects in that model.^[3] In macaques, AAV1-follistatin injected into the quadriceps increased regional muscle size and strength (roughly 12–27%) with no significant adverse effects over about 15 months.^[4] Limitation: all of this is animal data or localized gene therapy — not injectable protein in healthy humans.

Functional improvement in muscular dystrophy (only human efficacy data)

Claim: follistatin can improve real-world function in a muscle-wasting disease. Mechanism: increased fiber size and reduced fibrosis (scarring) from local myostatin/activin inhibition. Population: 6 patients with Becker muscular dystrophy in a Phase 1/2a gene-therapy trial. Effect: AAV1-FS344 delivered by direct quadriceps injection improved the six-minute-walk-test distance in responders (gains reported up to roughly 42–116 meters), with biopsies showing larger fibers and less fibrosis and no serious follistatin-related adverse events over follow-up.^[5] Limitation: tiny, open-label (no placebo group), a disease population rather than healthy adults, and — critically — gene therapy, not injectable protein. This is the single most important study to understand, and also the one most often misrepresented as evidence that "follistatin injections work."

Human proof-of-concept from genetics

Claim: blocking the myostatin pathway enlarges muscle in humans, not just animals. Mechanism: loss of myostatin signaling. Population: a single human infant with a homozygous loss-of-function mutation in the myostatin gene. Effect: the child showed gross muscle hypertrophy and increased strength with otherwise normal motor and mental development through age 4.5 years.^[6] Limitation: this is a natural genetic knockout, not a drug — it proves the pathway works in humans but says nothing about the safety or efficacy of dosing follistatin protein.

Anti-fibrotic effects (theoretical)

Claim: follistatin may reduce fibrosis (tissue scarring). Mechanism: activin, which promotes fibrosis in several organs, is neutralized by follistatin. Population: the muscle biopsies in the Becker trial showed reduced fibrosis;^[5] broader anti-fibrotic claims rest on activin biology. Limitation: this is a secondary observation in a small trial and a mechanistic inference, not a validated stand-alone benefit.

The bottom line on benefits

Follistatin has some of the most dramatic muscle-growth animal data of any compound on this site, plus a rare human proof-of-concept. But every scrap of human efficacy and safety evidence comes from localized gene therapy or a natural genetic mutation — neither of which tells you what happens when you inject follistatin protein subcutaneously. The research-community dose ranges below are extrapolations with no clinical validation.

Read this first — it's the most important dosing fact: there are no human clinical trials of injectable follistatin protein for muscle growth. The famous Mendell 2015 trial used AAV gene therapy — a single localized injection of a viral vector that then produces follistatin continuously inside the muscle — not the injectable protein sold as a research peptide.^[5] Gene therapy and injectable protein have completely different pharmacokinetics: one is local, sustained, and modest; the other is a brief systemic pulse with an entirely uncharacterized human profile. Everything below comes from research-community convention and animal studies, not validated clinical protocols. Treat it as a starting framework, not medical guidance.

Research-community protocols (injectable protein)

Protocol	Dose	Route	Frequency	Cycle
Conservative / first-time	100 mcg/day	Subcutaneous	Once daily	10–30 days
Standard (most common)	100–200 mcg/day	Subcutaneous	Once daily	10–30 days
Higher-dose	200–300 mcg/day	Subcutaneous	Once daily	10–30 days

FS-344 is the isoform in nearly all of these protocols, because once administered it cleaves into both FS-315 (circulating) and FS-288 (tissue-bound), giving both local and systemic coverage. Starting at 100 mcg/day for the first week to gauge tolerance is the more prudent approach given the total absence of human safety data. Effects on muscle protein synthesis are theorized to accumulate over a cycle rather than appear acutely, so don't expect an overnight change.

Reconstitution math, with a worked example

Follistatin is a large glycoprotein (roughly 37 kDa), not a small peptide — it is genuinely more fragile than compounds like BPC-157 or ipamorelin and needs gentler handling. The arithmetic of reconstitution is the same as any peptide: concentration = amount of powder ÷ volume of water added.

• Worked example: a 1 mg vial (1,000 mcg) reconstituted with 1 mL of bacteriostatic water gives 1,000 mcg/mL. To draw a 100 mcg dose you need 0.1 mL — which is 10 units on a standard 100-unit (1 mL) insulin syringe.
• More dilute, easier to measure: the same 1 mg vial with 2 mL of water gives 500 mcg/mL. A 100 mcg dose is then 0.2 mL, or 20 units — larger, easier-to-read volume with less measurement error.

Protein-specific technique: wipe the stopper with alcohol; inject the water slowly down the inside wall of the vial rather than blasting it directly onto the powder (mechanical force can denature the protein); do NOT shake — swirl gently and give it 5–10 minutes to dissolve; the solution should be clear and colorless — discard it if cloudy, particulate, or foamy. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a full walkthrough.

Timing, cycling, and stacking

• Timing: follistatin has no strict meal-timing requirement (unlike GH secretagogues). Pick a consistent daily time — morning, post-workout, or bedtime are all reasonable.
• Cycle length: 10–30 days of daily injection is the typical research-community cycle, followed by 30–60 days off. Three to four cycles per year is the conservative ceiling given the lack of long-term safety data.
• Stacking: combinations with GH secretagogues (CJC-1295 + ipamorelin) or IGF-1 LR3 are reported anecdotally as additive for muscle protein synthesis, but stacking multiple anabolic pathways at once compounds the (already uncharacterized) safety concerns. There is no validated combination protocol.

Storage — stricter than small peptides

• Lyophilized (powder) vials: −20°C or colder for long-term storage. A refrigerator (2–8°C) is acceptable short-term but not ideal.
• Reconstituted solution: refrigerate at 2–8°C and use within 7–14 days — substantially shorter than the ~28-day window typical of small peptides. Avoid freeze-thaw cycles; aliquot if needed. Protect from light and minimize room-temperature exposure during transport.

See the full peptide storage guide for details.

The honest framing: follistatin has one of the largest data gaps of any compound on this site. The published human safety data does not generalize to common research use. The Mendell 2015 trial delivered follistatin by localized AAV gene therapy into quadriceps muscle — minimal systemic spillover, a disease population, and only 6 patients.^[5] Injectable follistatin protein in healthy adults has essentially no formal safety data. Below are the reported and theoretical effects, grouped by how well-supported they are.

Reported / common (anecdotal)

• Injection-site reactions: the most commonly reported effect. Protein injections tend to produce more local irritation than small peptides. Rotate sites; usually mild and transient (24–72 hours).
• Headache, mild fatigue on initial use: anecdotal, usually transient.

The central concern — reproductive / FSH suppression (mechanistic)

This is the most clearly defined safety issue. Follistatin's natural role includes binding activin, which is essential for FSH secretion from the pituitary. The activin–FSH axis controls:

• In men: Sertoli-cell function, spermatogenesis, sperm count and motility.
• In women: ovarian follicle development, ovulation, and menstrual regularity.

Sustained systemic follistatin would predictably suppress FSH, with downstream fertility effects. The gene-therapy trial was localized to muscle with little systemic exposure, so reproductive effects weren't observed — but systemic injectable follistatin produces broader exposure and greater theoretical risk. Notably, the FS-344 isoform is favored in therapeutic development partly because it has lower affinity for activin than FS-288, specifically to limit this off-target FSH/reproductive effect.^[7] Reproductive-age individuals should consider pre- and post-cycle labs (FSH/LH/testosterone in men; a hormonal panel in women) to document any change.

Theoretical, but serious enough to warrant caution

• Immunogenicity: as an exogenous protein, follistatin can provoke antibody formation with repeated dosing, which may reduce efficacy over time. A loss of effect after weeks of use may signal this. (Gene therapy sidesteps the issue by producing the body's own follistatin.)
• Cardiac effects: myostatin is expressed in heart tissue and myostatin-knockout mice can develop cardiac hypertrophy. Whether chronic follistatin affects the human heart is unknown; the gene-therapy trial reported no cardiac adverse events, and the mouse durability study reported no adverse cardiac effects.^[3] Anyone with pre-existing cardiac disease should not use follistatin without cardiology supervision.
• Cancer / TGF-β signaling: the TGF-β pathway follistatin broadly inhibits has dual, context-dependent roles in cancer — tumor-suppressive in early-stage disease, tumor-promoting in advanced disease. No cancer signal appeared in the small trial, but sample size and follow-up are both tiny. Anyone with active or recent malignancy should avoid follistatin absent oncology supervision.
• Tendon / connective-tissue imbalance: rapid muscle hypertrophy outpacing tendon adaptation could theoretically raise injury risk.

Who should NOT use follistatin

• Anyone with active or recent malignancy (until oncology supervision).
• Reproductive-age individuals with fertility concerns, especially men in an active conception window.
• Anyone with pre-existing cardiac disease, particularly structural heart disease.
• Pregnant or breastfeeding individuals — no controlled data; contraindicated.
• People with severe hepatic or renal impairment, or active autoimmune disease (exogenous protein may amplify immune dysregulation).
• Anyone with known hypersensitivity to follistatin or formulation excipients.

Drug interactions

• Other anabolic peptides (IGF-1 LR3, MGF, GH secretagogues) or testosterone / SARMs: theoretically additive anabolic effect with compounded, uncharacterized cardiovascular and reproductive risk.
• Fertility medications: follistatin's FSH-suppressing effect directly opposes the goal of fertility drugs — do not combine.

What to do if you experience side effects

• Injection-site reactions: rotate sites, review technique; resolve in 24–72 hours.
• Loss of effect after weeks: possible antibody formation — discontinue and reassess.
• Decreased libido, fertility concerns, menstrual changes: stop and check hormonal labs; often resolves over weeks after discontinuation.
• Chest pain, palpitations, exercise intolerance: stop and seek cardiac evaluation.
• New nodule, mole change, unexplained weight loss, persistent pain: get an appropriate medical workup — the cancer concern is theoretical but real enough to take seriously.
• Sudden tendon pain or rupture, or any allergic reaction: seek care promptly.

Why this section matters: follistatin is an unregulated research compound, and it is a large, fragile protein rather than a simple peptide — which makes correct identity, purity, and cold-chain handling harder to guarantee and more important to verify. For an unproven compound, contamination and misidentification are arguably bigger practical risks than the molecule itself. Knowing how to read a Certificate of Analysis (COA) is the single most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight for the specific isoform (FS-344 is ~37 kDa as a glycoprotein).
• Batch-specific results: the COA should reference the exact lot you're buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected, and more so for a larger protein.
• Correct form and packaging: lyophilized powder in a sealed, light-protected vial that has been kept cold in transit.

Red flags

• No COA, or a COA from the seller rather than an independent lab.
• Pre-mixed "ready to use" liquid (follistatin is especially unstable in solution — this is a strong warning sign).
• No cold-chain shipping for a protein that degrades at room temperature.
• Prices far below market, or explicit human-use/medical claims (a sign of a non-compliant, higher-risk vendor).

Legal and regulatory status (2026)

• Not FDA-approved for any indication, in any country. No follistatin drug — protein or gene therapy — has received marketing approval.^[8]
• Human use is investigational gene therapy only: the furthest development is AAV1-follistatin (FS344), studied under IND/clinical-trial status for Becker and Duchenne muscular dystrophy (e.g., ClinicalTrials.gov NCT01519349).^[8]
• Injectable follistatin protein has zero clinical trials and no approved status; it is sold unregulated in the research-peptide market and is not a compounding-eligible substance.
• Sports: myostatin inhibitors including follistatin are prohibited by anti-doping authorities — competitive athletes should treat it as bannable.

For the complete legal picture, read Are Peptides Legal?

Follistatin is one of several strategies to block the myostatin pathway. None of these comparisons rest on head-to-head human trials — they contrast mechanisms and the available clinical outcomes. Follistatin's distinguishing feature is breadth: it traps myostatin, activin, and GDF-11 together, rather than hitting a single target.

Approach	Target	Status	Key point
Follistatin (FS-344)	Myostatin + activin + GDF-11	Gene therapy Phase 1/2a	Broadest inhibition; larger muscle effect than myostatin-only blockade, but broader off-target risk
Myostatin antibodies (e.g., domagrozumab)	Myostatin only	Discontinued	Highly specific, but failed efficacy endpoints in muscular-dystrophy trials
ActRIIB decoy receptor (ACE-031)	Multiple ActRIIB ligands	Discontinued	Potent, but halted over off-target safety signals
Bimagrumab (anti-ActRII antibody)	ActRII activation	Studied for metabolic indications	Increased lean mass and reduced fat mass in obesity trials

The repeated failure of myostatin-specific antibodies in dystrophy trials raised a real question: is blocking myostatin alone enough? Follistatin's better showing in the small Becker trial may reflect exactly its breadth — simultaneously silencing myostatin, activin, and other growth-limiting ligands.^[2][7] That same breadth, however, is why its safety questions (especially reproductive) are more complex than a single-target drug's.